Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis

Chronic Hand Dermatitis Clinical Trial

Official title:
Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis

Status Completed

Clinical Trial Summary

This pilot, phase II, 24-week study will recruit a total of 10 patients and will evaluate the efficacy and safety of acitretin in patients with severe chronic hand dermatitis .

Clinical Trial Description

Patients will receive acitretin once daily for a maximum of 24 weeks. Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study. Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24. The starting dose will be 10mg/day and, if well tolerated, will be increased in the first 4 weeks to a maximum of 30 mg/day. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01545284
Study type	Interventional
Source	Innovaderm Research Inc.
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	March 2012
Completion date	January 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01482663` - Chronic Hand Eczema - Self-management and Prognosis	N/A
Completed	`NCT00226707` - Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis	Phase 3
Active, not recruiting	`NCT05293717` - Topical Ruxolitinib in Chronic Hand Dermatitis	Phase 1/Phase 2
Completed	`NCT03728504` - Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema	Phase 2
Withdrawn	`NCT03741933` - Apremilast and Moderate to Severe Chronic Hand Dermatitis	Phase 4
Completed	`NCT00556855` - Comparison Study With E-DO in Chronic Hand Dermatitis	N/A